PAXG
PAXGCIK 0002076561
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (JEF 10-Q) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade PAXG commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed Nov 13, 2026 (period ending Sep 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Statements of Operations (Unaudited)
| Description | Three months ended September 30, 2026 | Three months ended September 30, 2025 | Nine months ended September 30, 2026 | Nine months ended September 30, 2025 |
|---|---|---|---|---|
| Formation and operating costs | - | 12,446 | - | 12,446 |
| Loss from operations | - | (12,446) | - | (12,446) |
| Interest income | 1 | 5 | 8 | 5 |
| Net income (loss) | 1 | (12,441) | 8 | (12,441) |
| Weighted average shares outstanding, basic and diluted (1) (2) | 4,285,714 | 4,285,714 | 4,285,714 | 4,285,714 |
| Basic and diluted net income (loss) per ordinary share | 0.00 | (0.00) | 0.00 | (0.00) |
Balance Sheets
| Description | September 30, 2026 (Unaudited) | December 31, 2025 (Audited) |
|---|---|---|
| Cash and cash equivalents | 1,882 | 13,714 |
| Total current assets | 1,882 | 13,714 |
| Deferred offering costs associated with proposed public offering | 189,794 | 122,592 |
| Total assets | 191,676 | 136,306 |
| LIABILITIES AND SHAREHOLDER’S EQUITY: | ||
| LIABILITIES: | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | 29,339 | 7,512 |
| Promissory note related party | 118,000 | 108,000 |
| Related party payable | 37,535 | 14,000 |
| Total current liabilities | 184,874 | 129,512 |
| Total liabilities | 184,874 | 129,512 |
| COMMITMENTS AND CONTINGENCIES (NOTE 6) | ||
| SHAREHOLDER’S EQUITY: | ||
| Preference shares, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding | - | - |
| Class A ordinary shares, $0.0001 par value, 500,000,000 shares authorized; none issued and outstanding | - | - |
| Class B ordinary shares, $0.0001 par value, 50,000,000 shares authorized; 4,928,571 issued and outstanding (1) (2) | 493 | 493 |
| Additional paid-in capital | 24,507 | 24,507 |
| Accumulated deficit | (18,198) | (18,206) |
| Total shareholder’s equity | 6,802 | 6,794 |
| Total liabilities and shareholder’s equity | 191,676 | 136,306 |
Statements of Cash Flows (Unaudited)
| Description | Nine months ended September 30, 2026 | Nine months ended September 30, 2025 |
|---|---|---|
| Net income (loss) | 8 | (12,441) |
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||
| Changes in operating assets and liabilities: | ||
| Accounts payable and accrued expenses | (3,238) | 1,699 |
| Net cash used in operating activities | (3,230) | (10,742) |
| Cash flows from financing activities: | ||
| Proceeds received from Sponsor under promissory note | 10,000 | 58,000 |
| Deferred offering costs associated with proposed public offering | (18,602) | (25,373) |
| Net cash provided by (used in) financing activities | (8,602) | 32,627 |
| Net change in cash | (11,832) | 21,885 |
| Cash and cash equivalents Beginning of period | 13,714 | - |
| Cash and cash equivalents End of period | 1,882 | 21,885 |
| Supplemental disclosure of non-cash financing activities: | ||
| Deferred offering costs included in accounts payable and accrued expenses | 29,338 | 6,550 |
| Deferred offering costs paid by Sponsor, recorded as related party payable | 23,535 | 12,620 |
Amounts as printed on the EDGAR/iXBRL face. Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗